Barclays initiated coverage on DaVita with a new price target
$DVA
Misc Health and Biotechnology Services
Health Care
Barclays initiated coverage of DaVita with a rating of Equal Weight and set a new price target of $133.00
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/6/2024 | $133.00 | Equal Weight | Barclays |
8/7/2023 | $100.00 → $142.00 | Neutral → Buy | UBS |
11/1/2022 | $97.00 → $72.00 | Buy → Hold | Deutsche Bank |
10/31/2022 | $117.00 → $74.00 | Buy → Neutral | UBS |
8/19/2022 | $106.00 → $117.00 | Buy | UBS |
6/21/2022 | $110.00 → $90.00 | Underperform | BofA Securities |
1/5/2022 | $114.00 → $125.00 | Hold | Truist Securities |
10/29/2021 | $113.00 → $111.00 | Sector Perform | RBC Capital |
11-K - DAVITA INC. (0000927066) (Filer)
8-K - DAVITA INC. (0000927066) (Filer)
8-K - DAVITA INC. (0000927066) (Filer)